LRRK2 and Parkinson disease: Further studies that identify the mechanisms by which LRRK2 reduction promotes LUAD tumorigenesis have the potential to benefit cancer patients, and to inform the design of LRRK2 inhibition strategies in Parkinson’s disease that mitigate potential pulmonary-related adverse effects.